Ong G, Ragetli R, Mnich K et al (2024) IRE1 signaling increases PERK expression during chronic ER stress
Health Focus: Tendon and ligament healing, gut repair (leaky gut, gut dysbiosis, inflammatory bowel disease [IBD]), joint recovery, brain injury support
Six patients achieved complete clinical remission
(2022) demonstrated that combined GLP-1/GIP/glucagon co-agonism produced approximately 3040% greater fat mass reduction in preclinical models compared to GLP-1/GIP dual agonism alone at matched doses
Potential benefits of MOTS-c: Improved insulin sensitivity Better glucose control Increased exercise capacity Enhanced mitochondrial function Improved metabolic flexibility Unlike Semaglutide or Tirzepatide, MOTS-c does not primarily work by reducing appetite
[DOI] [PMC free article] [PubMed] [Google Scholar] 147.Meyers PA